ERC Society for Endocrinology Archive
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Endocrine-Related Cancer 6 (3) 349-371    DOI: 10.1677/erc.0.0060349
Copyright © 1999 by the Society for Endocrinology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Green, S
Right arrow Articles by Furr, B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Green, S
Right arrow Articles by Furr, B
Endocrine Related Cancer, Vol 6, Issue 3, 349-371
Copyright © 1999 by Society for Endocrinology


Articles

Prospects for the treatment of endocrine-responsive tumours

S Green and B Furr


Much has been achieved over the last 30 years to improve the treatment of hormone-dependent cancer of the breast, ovary and prostate. The development of the antioestrogen tamoxifen (Nolvadex) spear-headed a range of drugs that counter the growth-promoting action of the female and male sex steroid hormones. An important additional benefit of endocrine therapies has been their low toxicity compared with conventional cancer chemotherapy thereby providing effective treatment with few serious side-effects and a sustained quality of life. Although some currently available therapies improve patient disease-free survival and overall survival, particularly when given in an adjuvant setting, they are not cures. There is, therefore, a continued need to develop newer therapies that extend the effectiveness of those currently available. This is particularly important when tumours either fail to respond or develop resistance to endocrine therapy. In this review, we examine how our improved understanding of the factors that influence the progression of endocrine-related tumours is leading to the development of novel therapies to treat both hormone-dependent and -independent tumours.


This article has been cited by other articles:


Home page
Biol. Reprod.Home page
F. C.A. Santos, A. M.G. Custodio, S. G.P. Campos, P. S.L. Vilamaior, R. M. Goes, and S. R. Taboga
Antiestrogen Therapies Affect Tissue Homeostasis of the Gerbil (Meriones unguiculatus) Female Prostate and Ovaries
Biol Reprod, October 1, 2008; 79(4): 674 - 685.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
R. Kim, M. Kaneko, K. Arihiro, M. Emi, K. Tanabe, S. Murakami, A. Osaki, and K. Inai
Extranuclear expression of hormone receptors in primary breast cancer
Ann. Onc., August 1, 2006; 17(8): 1213 - 1220.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. J. Bettoun, A. Scafonas, S. J. Rutledge, P. Hodor, O. Chen, C. Gambone, R. Vogel, S. McElwee-Witmer, C. Bai, L. Freedman, et al.
Interaction between the Androgen Receptor and RNase L Mediates a Cross-talk between the Interferon and Androgen Signaling Pathways
J. Biol. Chem., November 25, 2005; 280(47): 38898 - 38901.
[Abstract] [Full Text] [PDF]


Home page
DevelopmentHome page
B. Gerisch and A. Antebi
Hormonal signals produced by DAF-9/cytochrome P450 regulate C. elegans dauer diapause in response to environmental cues
Development, April 15, 2004; 131(8): 1765 - 1776.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
K. H. Burns, J. E. Agno, L. Chen, B. Haupt, S. C. Ogbonna, K. S. Korach, and M. M. Matzuk
Sexually Dimorphic Roles of Steroid Hormone Receptor Signaling in Gonadal Tumorigenesis
Mol. Endocrinol., October 1, 2003; 17(10): 2039 - 2052.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. M. Moretti, M. Montagnani Marelli, J. C. Van Groeninghen, and P. Limonta
Locally Expressed LHRH Receptors Mediate the Oncostatic and Antimetastatic Activity of LHRH Agonists on Melanoma Cells
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3791 - 3797.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the Society for Endocrinology.